Administration of Goserelin at Alternative Injection Sites for Premenopausal Breast Cancer

Of 26 patients who received goserelin at an AIS, all patients reported the absence of menses with no tolerability concerns. For patients who may want to avoid abdominal administration, injection of goserelin at an AIS appears to be a viable strategy and offers flexibility for OFS management in breast cancer.